greeksoup/ stock research
Stock research / United States / MMM · Surgical & Medical Instruments & Apparatus · NYSE

3M Co. (MMM)

3M is a diversified technology company. It was incorporated in Delaware in 1929 to continue operations begun in 1902, and trades under the ticker MMM. Most of what it sells involves expertise in product development, manufacturing and marketing, and competes with products made by other technologically oriented companies. At the end of 2025 it employed approximately 60,500 people on a full-time equivalent basis, approximately 22,500 in the United States and 38,000 internationally. Continuing operations run in three reportable segments: Safety and Industrial, Transportation and Electronics, and Consumer. The filing states that the segments exist to bring together common or related 3M technologies, which helps develop products and lets business resources be shared efficiently.

3M Co.

3M is a diversified technology company. It was incorporated in Delaware in 1929 to continue operations begun in 1902, and trades under the ticker MMM. Most of what it sells involves expertise in product development, manufacturing and marketing, and competes with products made by other technologically oriented companies. At the end of 2025 it employed approximately 60,500 people on a full-time equivalent basis, approximately 22,500 in the United States and 38,000 internationally. Continuing operations run in three reportable segments: Safety and Industrial, Transportation and Electronics, and Consumer. The filing states that the segments exist to bring together common or related 3M technologies, which helps develop products and lets business resources be shared efficiently.

Safety and Industrial

The divisions are abrasives, automotive aftermarket, electrical markets, industrial adhesives and tapes, the industrial specialties division, personal safety and roofing granules. What that means in practice is industrial abrasives and finishing for metalworking; autobody repair solutions; industrial specialty products such as personal hygiene products, masking and packaging materials; electrical products and materials for construction and maintenance, power distribution and electrical original equipment manufacturers; structural adhesives and tapes; respiratory, hearing, eye and fall protection; and natural and colour-coated mineral granules for shingles.

Transportation and Electronics

The divisions are advanced materials, automotive and aerospace, commercial branding and transportation, display materials and systems, and electronics materials solutions. The activities named are advanced ceramic solutions; attachment and bonding, films, and sound and temperature management for vehicles; large format graphic films for advertising and fleet signage; reflective signage for highways and vehicle safety; light management films and electronics assembly solutions; aerospace and industrial and commercial solutions; chip packaging and interconnection; semiconductor production materials; and solutions for data centres.

Consumer

The divisions are consumer safety and well-being, home and auto care, home improvement, and packaging and expression. The activities named are cleaning products for the home, consumer air quality products, picture hanging accessories, and retail abrasives, paint accessories and safety products. Some seasonality affects this segment, for example around back-to-school and the holidays.

How the products reach the buyer

3M sells through numerous distribution channels: directly to users, and through a wide range of e-commerce and traditional wholesalers, retailers, jobbers, distributors and dealers across many trades and countries. The filing attributes much of the company's position and growth to the confidence those partners have built through long association with its marketing and sales representatives, and says the company is working to strengthen and optimise that route to market, improve partner engagement and lift channel performance.

On raw materials, the filing reports that during 2025 persistent pricing pressure, tariffs and geopolitical uncertainty prompted producers to adjust capacity and restructure operations, which caused supply constraints and inflation, offset through negotiated supply contracts and by using the company's scale across its supply base.

From 3M's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in 3M became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 20 October 2026
Revenue
$6.6 billion
+1.0% on the year · +1.3% on the quarter
Q4 FY2024Q3 FY2026
Net income
$1.4 billion
+64.6% on the year · +47.2% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$2.63
+69.7% on the year · +47.8% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 3 February 2026
Revenue
$24.9 billion
+1.5% on the year
FY2018FY2025
Net income
$3.2 billion
-22.1% on the year
FY2018FY2025
Diluted EPS
$6.00
-20.5% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in words3M (MMM) reported revenue of $24.9 billion for fiscal 2025, the year ended 31 December 2025, up 1.5% on the year before. Net income was $3.2 billion and diluted earnings per share $6.00. Revenue was $24.6 billion in fiscal 2024, $24.6 billion in fiscal 2023, $26.2 billion in fiscal 2022 and $35.4 billion in fiscal 2021. Net income in the same years was $4.2 billion, a loss of $7.0 billion, $5.8 billion and $5.9 billion. Over the twelve months to 30 September 2026, 3M reported revenue of $25.2 billion and net income of $3.5 billion. Revenue fell 5.0% a year, compounded, over the five years to fiscal 2025. 3M declared $3.07 a share in dividends over the last four quarters and had 517 million shares outstanding at the latest filed count. At 30 September 2026 it carried $15.0 billion of debt and $4.8 billion of cash. At the close of 6 November 2026 the market cap of 3M was $95.7 billion, 27.6 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE85.7%
ROCE24.8%
Operating margin18.8%
Net margin14.0%
FCF margin10.6%
Interest cover5.5x
Debt to equity3.63x
Cash conversion1.03x
Share count, last 12 months-2.7%
Sales CAGR, 3 years-1.6%
Profit CAGR, 3 years-17.4%
EPS, TTM$6.71

At the close of 6 November 2026

Price$185.24
Market cap$95.7 billion
Stock P/E27.6x
Price to book23.2x
EV / EBITDA17.2x
Dividend yield1.7%
Market cap / sales3.8x
52-week high$193.98
52-week low$141.20
Price, 1 year13.1%
Price CAGR, 3 years33.0%
Price CAGR, 5 years3.8%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as 3M Co. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
MMMgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023Q1 FY2024 †Q2 FY2024Q3 FY2024Q4 FY2024 †Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue8,6128,8298,7028,6198,0796,0556,2836,2706,0026,0166,2556,2946,0105,9546,3446,5176,1336,0306,5006,584
Cost of revenue4,6984,8265,0934,7284,5853,7443,7283,7163,7953,4853,5713,6473,7443,4783,6463,7924,0753,5743,8173,801
Gross profit3,9144,0033,6093,8913,4942,3112,5552,5542,2072,5312,6842,6472,2662,4762,6982,7252,0582,4562,6832,783
Gross margin45%45%41%45%43%38%41%41%37%42%43%42%38%42%43%42%34%41%41%42%
SG&A1,8241,8823,0231,9982,1461,70511,6155,4191,6251,1281,1321,0628999451,2678209657441,061921
Operating income1,6161,6411104,1566321,241-9,358-3,0961,2431,1491,2721,3161,0851,2461,1401,4477961,3979841,558
Operating margin19%19%1%48%8%20%-149%-49%21%19%20%21%18%21%18%22%13%23%15%24%
Interest expense118113128106115123144304371385322276252255237232222214202217
Pre-tax income1,5641,60360.04,1325971,189-9,430-3,3021,0009291,4101,7217591,3859231,1477588781,1201,670
Tax rate15%19%-38%7%10%18%n/an/a6%24%14%20%4%19%27%27%24%25%16%16%
Net income1,3391,29978.03,859541976-6,841-2,0759459281,1451,3727281,1167238345776539331,373
Net margin16%15%1%45%7%16%-109%-33%16%15%18%22%12%19%11%13%9%11%14%21%
Diluted EPS$2.31$2.26$0.14$6.77$0.98$1.76-$12.35-$3.74$1.70$1.67$2.07$2.48$1.33$2.04$1.34$1.55$1.07$1.23$1.78$2.63
Operating cash flow2,0051,0111,1271,5311,9221,2751,5091,9101,9867671,021-1,7871,818-79.0-9541,7561,583574986486
Capital expenditure556424384435506475377405358375269246291236208218248225223256
Free cash flow1,4495877431,0961,4168001,1321,5051,628392752-2,0331,527-315-1,1621,5381,335349763230
Buybacks9387730.015553629.00.02.02.021.04006757051,2749534725521,999994232
Dividends paid848852848850819827828828828835386383378396390389387412401403
Shares outstanding572m569m570m553m549m552m552m552m553m553m549m545m539m538m533m531m530m522m516m517m
Filing10-K10-Q10-Q10-Q10-K10-K10-Q10-Q10-K10-K10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009FY2010FY2011FY2012FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020 †FY2021 †FY2022 †FY2023 †FY2024FY2025TTM
Revenue24,46225,26923,12326,66229,61129,90430,87131,82130,27430,10931,65732,76532,13632,18435,35526,16124,61024,57524,94825,247
Cost of revenue12,73513,37912,10913,83115,69315,68516,10616,44715,35115,11816,05516,68217,13616,60518,79515,85314,98314,44714,99115,267
Gross profit11,72711,89011,01412,83113,91814,21914,76515,37414,92314,99115,60216,08315,00015,57916,56010,3089,62710,1289,9579,980
Gross margin47.9%47.1%47.6%48.1%47.0%47.5%47.8%48.3%49.3%49.8%49.3%49.1%46.7%48.4%46.8%39.4%39.1%41.2%39.9%39.5%
Research and developmentn/a8518389191,0361,0791,1501,1931,2201,2481,3521,2531,2531,1001,200800700700n/an/a
Selling, general and administrative5,0155,2454,9075,4796,1706,1026,3846,4696,2336,3116,6267,6027,0296,9297,1977,23219,1984,2213,9973,691
Operating income6,1935,2184,8145,9186,1786,4836,6667,1356,9807,0277,6927,2076,1747,1617,3694,369-10,6894,8224,6294,735
Operating margin25.3%20.6%20.8%22.2%20.9%21.7%21.6%22.4%23.1%23.3%24.3%22.0%19.2%22.3%20.8%16.7%-43.4%19.6%18.6%18.8%
Interest expensen/an/an/an/an/an/an/an/a1491993223504485294884629421,191946855
Pre-tax income6,1155,1084,6325,7556,0316,3516,5627,0266,8237,0537,5487,0005,7126,7957,2044,204-11,2714,8194,2134,426
Income tax1,9641,5881,3881,5921,6741,8401,8412,0281,9821,9952,6791,6371,1141,3371,285188-2,8678041,003850
Effective tax rate32.1%31.1%30.0%27.7%27.8%29.0%28.1%28.9%29.0%28.3%35.5%23.4%19.5%19.7%17.8%4.5%n/a16.7%23.8%19.2%
Net income4,0963,4603,1934,0854,2834,4444,6594,9564,8335,0504,8585,3494,5175,4495,9215,777-6,9954,1733,2503,536
Net margin16.7%13.7%13.8%15.3%14.5%14.9%15.1%15.6%16.0%16.8%15.3%16.3%14.1%16.9%16.7%22.1%-28.4%17.0%13.0%14.0%
Diluted EPS$5.60$4.89$4.52$5.63$5.96$6.32$6.72$7.49$7.58$8.16$7.93$8.89$7.72$9.36$10.12$10.18-$12.63$7.55$6.00$6.71
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2009 to FY2025

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Safety and Industrialn/an/an/an/an/an/an/an/a11,94612,41411,49010,97211,98111,60410,95610,96111,38446.3%
Transportation and Electronicsn/an/an/an/an/an/an/an/a9,86110,1049,5958,4069,2628,9028,5018,3808,27233.7%
Consumern/an/an/an/a4,4354,5234,4294,5785,0065,1275,1294,9765,5135,2925,0264,9314,92020.0%
Consumer And Office3,4713,8534,1534,316n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Display And Graphics3,1323,8843,6743,560n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Electro And Communications2,3873,0433,3063,228n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Electronics And Energyn/an/an/an/a5,3935,6085,0694,926n/an/an/an/an/an/an/an/an/an/a
Health Care4,2824,5135,0315,1585,3345,5725,4495,6066,6356,8217,4317,8328,597n/an/an/an/an/a
Industrialn/an/an/an/a10,65710,98510,38811,217n/an/an/an/an/an/an/an/an/an/a
Industrial And Transportation7,1208,42910,07310,346n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Safety And Graphicsn/an/an/an/a5,5845,7325,7365,948n/an/an/an/an/an/an/an/an/an/a
Safety Security And Protection Services3,0763,3163,8213,802n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Corporate And Unallocated1310115n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Elimination Of Dual Credit-358-386-458-511n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Sales between segments, taken outn/an/an/an/a-532-599-797-2,166-1,791-1,701-1,509n/an/an/an/an/an/an/a
Safety and Industrial FY2017 to FY2025Transportation and Electronics FY2017 to FY2025Consumer FY2013 to FY2025Health Care FY2009 to FY2021Industrial FY2013 to FY2016Safety And Graphics FY2013 to FY2016Electronics And Energy FY2013 to FY2016Industrial And Transportation FY2009 to FY2012Consumer And Office FY2009 to FY2012Display And Graphics FY2009 to FY2012Safety Security And Protection Services FY2009 to FY2012Electro And Communications FY2009 to FY2012
27.0FY201031.4FY201332.3FY201633.6FY201925.8FY202224.6FY2025

$ billion; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Corporate And Unallocated, Elimination Of Dual Credit and Sales between segments, taken out are the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.

Profit by segment FY2009 to FY2025

The operating profit each segment reports. Costs 3M does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Margin
FY2025
Safety and Industrialn/an/an/an/an/an/an/an/a2,6032,8602,3732,5882,4601,1352,3242,4912,83624.9%
Transportation and Electronicsn/an/an/an/an/an/an/an/a2,9862,6432,1191,7011,8699731,3121,5781,43617.4%
Consumern/an/an/an/a9459951,0481,0541,0511,0841,0751,1191,16497890493299620.2%
Consumer And Office748840840930n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Display And Graphics590946788693n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Electro And Communications351670712691n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Electronics And Energyn/an/an/an/a9541,1221,0831,145n/an/an/an/an/an/an/an/an/an/a
Health Care1,3471,3621,4891,6461,6721,7241,7301,7311,8771,9181,7961,6622,034n/an/an/an/an/a
Industrialn/an/an/an/a2,3072,3812,2772,528n/an/an/an/an/an/an/an/an/an/a
Industrial And Transportation1,2301,7542,0572,258n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Safety And Graphicsn/an/an/an/a1,2271,2961,3321,403n/an/an/an/an/an/an/an/an/an/a
Safety Security And Protection Services728709814847n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Safety and Industrial FY2017 to FY2025Industrial FY2013 to FY2016Industrial And Transportation FY2009 to FY2012Transportation and Electronics FY2017 to FY2025Consumer And Office FY2009 to FY2012Safety And Graphics FY2013 to FY2016Consumer FY2013 to FY2025Display And Graphics FY2009 to FY2012Health Care FY2009 to FY2021Electronics And Energy FY2013 to FY2016Safety Security And Protection Services FY2009 to FY2012Electro And Communications FY2009 to FY2012
6,281FY20107,105FY20137,861FY20167,363FY20193,086FY20225,268FY2025

$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.

FY2025Share of salesShare of profit
Safety and Industrial46%54%
Transportation and Electronics34%27%
Consumer20%19%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by region FY2009 to FY2025, 4 years left out

FY2009FY2010FY2011FY2012FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Americasn/an/an/an/an/a15,86416,12416,52518,09713,395n/a13,40513,57954.4%
Asia Pacific6,1208,2599,1089,0929,80910,2549,7969,56910,6008,4537,0686,9947,09528.4%
Europe, Middle East and Africa5,9726,2597,0766,7306,4566,6546,2266,1096,6604,3134,2744,1764,27417.1%
China/Hong Kongn/an/an/an/an/an/an/an/an/an/a2,625n/an/an/a
Latin America and Canada2,5162,9503,4113,5723,033n/an/an/an/an/an/an/an/an/a
United States8,5099,21010,02810,52812,372n/an/an/an/an/a10,607n/an/an/a
Other Unallocated6-16-12-18n/an/an/an/an/an/an/an/an/an/a
Americas FY2018 to FY2025Asia PacificEurope, Middle East and AfricaUnited States FY2009 to FY2023China/Hong Kong FY2023Latin America and Canada FY2009 to FY2017
23.1FY200929.6FY201131.7FY201732.1FY201935.4FY202124.6FY202324.9FY2025

$ billion; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Other Unallocated is the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.

Cash flow

FY2007FY2008FY2009FY2010FY2011FY2012FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020 †FY2021 †FY2022 †FY2023 †FY2024FY2025TTM
Operating cash flow4,2464,5334,9415,1745,2845,3005,8176,6266,4206,6626,2406,4397,0708,1137,4545,5916,6801,8192,3063,629
Capital expenditure1,4221,4719031,0911,3791,4841,6651,4931,4611,4201,3731,5771,6991,5011,6031,7491,6151,181910952
Free cash flow2,8243,0624,0384,0833,9053,8164,1525,1334,9595,2424,8674,8625,3716,6125,8513,8425,0656381,3962,677
Free cash flow margin11.5%12.1%17.5%15.3%13.2%12.8%13.4%16.1%16.4%17.4%15.4%14.8%16.7%20.5%16.5%14.7%20.6%2.6%5.6%10.6%
Cash from investing-1,367-2,399-1,732-2,689n/an/an/an/a-2,817-1,403-3,086222-6,444-580-1,317-1,046-1,207-3,2061,350-2,917
Cash from financing-2,518-1,766-2,014-2,121n/an/an/an/a-3,648-4,626-2,655-6,701-1,124-5,300-6,145-5,350-3,1471,098-4,016-592
Depreciation and amortisation1,0721,1531,1571,1201,2361,2881,3711,4081,4351,4741,5441,4881,5931,9111,9151,8311,9871,3631,3081,427
Share-based compensation228202217274253223240280276298324302278262274263274289225210
Buybacks3,2391,63117.08542,7012,2045,2125,6525,2383,7532,0684,8701,4073682,1991,46433.01,8013,2513,777
Dividends paid1,3801,3981,4311,5001,5551,6351,7302,2162,5612,6782,8033,1933,3163,3883,4203,3693,3111,9821,5621,603
Dividend per share$1.92$2.00$2.04$2.10$2.20$2.36$2.54$3.59$3.08$4.44$4.70$5.44$5.76$5.88$5.92$5.96$6.00$3.61$2.92n/a
Diluted shares, weighted732m707m707m726m719m703m694m662m637m619m613m602m585m582m585m568m554m552m541m523m
Shares outstanding at period endn/a694m711m712m695m687m663m635m609m597m595m577m575m578m572m549m553m539m530m517m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009FY2010FY2011FY2012FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020 †FY2021 †FY2022 †FY2023 †FY2024FY2025TTM
Funded by
Shareholders' equity12,0729,88012,76415,66315,42017,57517,50213,10911,42910,29811,5639,79610,06312,86715,04614,7224,8073,8424,7024,127
Non-controlling interestn/a42453835444246544633.039.045.059.052.063.064.071.048.061.052.045.042.0
Redeemable equityn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a0.0971
Debtn/a5,1665,6195,4525,1666,0016,0096,81110,79711,65013,94914,62220,31318,78317,34715,93916,03513,04412,60214,994
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a607609591580464405363450
Finance lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/a75.011193.093.075.060.047.0n/an/a
Other liabilitiesn/a10,3238,3298,68710,5889,8359,34711,42110,61810,91312,41611,95513,50214,92813,92415,09129,15322,47820,02118,942
Total liabilities and equityn/a25,79327,25030,15631,61633,87633,30431,37432,88332,90637,98736,50044,65947,34447,07246,45550,58039,86837,73339,526
Owned
Fixed assetsn/a6,8867,0007,2797,6668,3788,6528,4898,5158,5168,8668,7389,3339,4219,4299,1787,6907,3887,1016,969
Goodwilln/a5,7535,8326,8207,0477,3857,3457,0509,2499,16610,51310,05113,44413,80213,4866,3376,3826,2816,4197,344
Intangible assetsn/a1,3981,3421,8201,9161,9251,6881,4352,6012,3202,9362,6576,3795,8355,2884,6991,3231,2101,1032,052
Investmentsn/a7251,5691,6412,3571,8118781,5412352971,103417141434n/an/an/an/an/an/a
Securities held for sale or to maturityn/an/an/an/an/an/an/an/an/an/an/an/an/an/a22826170.02,144710n/a
Cash and equivalents1,8961,8493,0403,3772,2192,8832,5811,8971,7982,3983,0532,8532,3534,6344,5643,6555,9335,6005,2354,835
Receivablesn/a3,1953,2503,6153,8674,0614,2534,2384,1544,3924,9115,0204,7914,7054,6604,5323,6013,1943,5334,116
Inventoryn/a3,0132,6393,1553,4163,8373,8643,7063,5183,3854,0344,3664,1344,2394,9855,3723,9443,6983,6614,081
Other assetsn/a2,9742,5782,4493,1283,5964,0433,0182,8132,4322,5712,3984,0844,2744,43212,42121,63710,3539,97110,129
Total assetsn/a25,79327,25030,15631,61633,87633,30431,37432,88332,90637,98736,50044,65947,34447,07246,45550,58039,86837,73339,526
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded-1.9%-5.0%-1.6%1.7%
Profit growth, compounded-3.9%-9.8%-17.4%4.0%
Return on equity, average34.4%22.2%10.7%69.1%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was 3M's revenue in fiscal 2025?

3M (MMM) reported revenue of $24.9 billion for fiscal 2025, the year ended 31 December 2025, up 1.5% on the year before.

How much did 3M earn in fiscal 2025?

Net income was $3.2 billion for fiscal 2025, and diluted earnings per share $6.00.

What is 3M's P/E ratio?

At the close of 6 November 2026, 3M traded at 27.6 times its earnings over the twelve months to 30 September 2026.

What is 3M's market cap?

The market cap of 3M was $95.7 billion at the close of 6 November 2026.

Does 3M pay a dividend?

Yes. 3M declared $3.07 a share in dividends over the four quarters to 30 September 2026.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
70 companies share its SEC industry code (Surgical & Medical Instruments & Apparatus); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on MMM

Dividends$3.07 a share over the four quarters to 30 September 2026, a 1.66% yield
Filings22 in twelve months: 12 current reports (8-K), about 4 results of operations; 3 material agreement; 2 other events; 2 new financial obligation; 2 officer or director change
Planned insider sales14 Form 144 notices in twelve months, $20.7 million; latest 5 August 2026
Options tapeput/call 0.53 by open interest at the 6 November 2026 close; the straddle prices a 3.4% move to 13 November 2026
13F holders2,254 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading58 sales and 4 purchases on Form 4 in twelve months
Congress2 House trades disclosed in six months
Short interest10.0 million shares short, 3.66 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202620 October 2026EDGAR
10-Q30 June 202621 July 2026EDGAR
10-Q31 March 202621 April 2026EDGAR
10-K31 December 20253 February 2026EDGAR
10-Q30 September 202521 October 2025EDGAR
10-Q30 June 202518 July 2025EDGAR
10-Q31 March 202522 April 2025EDGAR
10-K31 December 20245 February 2025EDGAR
10-Q30 September 202422 October 2024EDGAR
10-Q30 June 202426 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.